US Patent

US8679544 — Formulation of diclofenac

Formulation · Assigned to Iceutica Pty Ltd · Expires 2030-04-23 · 4y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for producing particles of diclofenac using dry milling processes and compositions comprising diclofenac.

USPTO Abstract

The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
US8679544
Jurisdiction
US
Classification
Formulation
Expires
2030-04-23
Drug substance claim
No
Drug product claim
Yes
Assignee
Iceutica Pty Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.